338840.KQ Y-Biologics, Inc.
- Market cap
- KRW 138B
- P/E
- -
- P/B
- 8.00x
- ROE
- -141.2%
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 338840.KQ undervalued?
Graham numberThe Graham number of Y-Biologics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Y-Biologics, Inc. fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-141.2%), below 10%.
ROA 0/1
Return on assets (-48.4%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-535.4%) is below the industry median (4.8%).
Revenue Growth 0/2
Revenue shrank 11.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (93.6%), up to 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 0/2
Cash covers 0.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (8.0x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Y-Biologics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Y-Biologics, Inc.
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the …
Full company profileY-Biologics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Y-Biologics, Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 4.85B | 4.15B | 3.48B | 5.76B | 2.91B | 3.66B |
| Gross Profit | 2.39B | 1.34B | 2.39B | 4.37B | 2.38B | 3.08B |
| Operating Income | -17.4B | -18.7B | -21.4B | -7.12B | -9.27B | -15.3B |
| EBITDA | - | -15.7B | -18.4B | -4.36B | -38.8B | -12.6B |
| Net Income | -17.1B | -18.8B | -20.9B | -6.44B | -42.0B | -24.3B |
| EPS | -1,231 | -1,356 | -1,414 | -436 | -2,769 | -1,600 |
| Balance Sheet | ||||||
| Total Assets | 38.2B | 29.3B | 30.3B | 21.7B | 55.8B | 50.2B |
| Total Liabilities | 9.80B | 17.0B | 6.89B | 3.37B | 29.2B | 33.0B |
| Shareholders' Equity | 28.4B | 12.3B | 23.4B | 18.4B | 26.6B | 17.2B |
| Cash & Short-term Investments | 16.9B | 13.0B | 20.9B | 12.2B | 38.9B | 2.51B |
| Cash Flow | ||||||
| Operating Cash Flow | -9.17B | -10.1B | -7.61B | -4.14B | -5.84B | -10.2B |
| Capital Expenditure | 7.57B | 1.10B | 196M | 2.86B | 1.42B | 2.24B |
| Free Cash Flow | -16.7B | -11.2B | -7.80B | -7.00B | -7.26B | -12.4B |
| Ratios | ||||||
| ROE | -60.0% | -153.0% | -89.2% | -35.1% | -158.0% | -141.2% |
| ROA | -44.6% | -64.1% | -68.9% | -29.6% | -75.3% | -48.4% |
| Net Profit Margin | -352.2% | -453.1% | -599.9% | -111.8% | -1,442.7% | -663.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Y-Biologics, Inc. dividends
Y-Biologics, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Y-Biologics, Inc.
- Insiders 29.28%
- Institutions 2.17%
- Public & others 68.55%
- Shares outstanding 15.4M
- Free float 10.8M
Y-Biologics, Inc. company profile
- Company name
- Y-Biologics, Inc.
- Ticker
- 338840.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- #715-B, 17 Techno 4-ro, Daejeon, South Korea
- Phone
- 82 4 2867 9971
- Website
- ybiologics.com
About Y-Biologics, Inc.
Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 and is headquartered in Daejeon, South Korea.
Y-Biologics, Inc. management
7- Mr. Young Woo ParkCEO, President & Director · born 1956
- Woo-Ik JangCEO & Representative Director · born 1956
- Mr. Yeon Kyung LeeChief Financial Officer
- Mr. Bum Chan ParkSenior VP, CTO & Director
- Ms. Myeong Ja JangDirector of Legal/IP
- Sang-heon LeeExecutive Director · born 1967
- Joo-han YoonExecutive Director · born 1972